These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 2124411)

  • 21. Transdermal drug delivery system (TDDS) adhesion as a critical safety, efficacy and quality attribute.
    Wokovich AM; Prodduturi S; Doub WH; Hussain AS; Buhse LF
    Eur J Pharm Biopharm; 2006 Aug; 64(1):1-8. PubMed ID: 16797171
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transdermal nitroglycerin (glyceryl trinitrate). A review of its pharmacology and therapeutic use.
    Todd PA; Goa KL; Langtry HD
    Drugs; 1990 Dec; 40(6):880-902. PubMed ID: 2127741
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transdermal clonidine. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.
    Langley MS; Heel RC
    Drugs; 1988 Feb; 35(2):123-42. PubMed ID: 3281820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In Vitro Drug Transfer Due to Drug Retention in Human Epidermis Pretreated with Application of Marketed Estradiol Transdermal Systems.
    Krishnaiah YSR; Pavurala N; Yang Y; Manda P; Katragadda U; Yang Y; Shah R; Fang G; Khan MA
    AAPS PharmSciTech; 2017 Aug; 18(6):2131-2140. PubMed ID: 28028793
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Skin sensitivity and transdermal drug delivery. A review of the problem.
    Carmichael AJ
    Drug Saf; 1994 Feb; 10(2):151-9. PubMed ID: 8011180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variational analysis of the transdermal delivery rate from two prototypical ethanol-water nitroglycerin TTS devices and Transderm-Nitro 10 in the normal population.
    Kochak GM; Berner B; Leal M; Sambol NC
    J Pharmacokinet Biopharm; 1992 Oct; 20(5):443-59. PubMed ID: 1287196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transdermal nitroglycerin in angina pectoris.
    Abrams J
    Eur Heart J; 1989 May; 10 Suppl A():11-9. PubMed ID: 2501090
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transdermal dosage forms.
    Shaw JE
    Methods Enzymol; 1985; 112():448-61. PubMed ID: 3930919
    [No Abstract]   [Full Text] [Related]  

  • 29. Acute and chronic antianginal efficacy of continuous twenty-four-hour application of transdermal nitroglycerin. Steering Committee, Transdermal Nitroglycerin Cooperative Study.
    Am J Cardiol; 1991 Nov; 68(13):1263-73. PubMed ID: 1951111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Principles of transdermal nitroglycerin administration.
    Wolff HM; Bonn R
    Eur Heart J; 1989 May; 10 Suppl A():26-9. PubMed ID: 2501091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparative evaluation of two transdermal nitroglycerin delivery systems: Nitro-Dur versus Transderm-Nitro. The Collaborative Investigation Group.
    Clin Ther; 1991; 13(5):545-9. PubMed ID: 1799911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transdermal drug delivery systems and skin sensitivity reactions. Incidence and management.
    Murphy M; Carmichael AJ
    Am J Clin Dermatol; 2000; 1(6):361-8. PubMed ID: 11702612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transdermal hormonal contraception: benefits and risks.
    Burkman RT
    Am J Obstet Gynecol; 2007 Aug; 197(2):134.e1-6. PubMed ID: 17689623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and validation of in vitro-in vivo correlation (IVIVC) for estradiol transdermal drug delivery systems.
    Yang Y; Manda P; Pavurala N; Khan MA; Krishnaiah YS
    J Control Release; 2015 Jul; 210():58-66. PubMed ID: 25979329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transdermal drug delivery and cutaneous metabolism.
    Guy RH; Hadgraft J; Bucks DA
    Xenobiotica; 1987 Mar; 17(3):325-43. PubMed ID: 3107225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fabrication and characterization of matrix type transdermal patches loaded with tizanidine hydrochloride: potential sustained release delivery system.
    Shahid N; Siddique MI; Razzaq Z; Katas H; Waqas MK; Rahman KU
    Drug Dev Ind Pharm; 2018 Dec; 44(12):2061-2070. PubMed ID: 30081679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Therapeutic systems--possibilities and limits].
    Meinertz T; Jähnchen E; Just H
    Verh Dtsch Ges Inn Med; 1988; 94():436-41. PubMed ID: 3144813
    [No Abstract]   [Full Text] [Related]  

  • 38. Are all estrogens created equal? A review of oral vs. transdermal therapy.
    Goodman MP
    J Womens Health (Larchmt); 2012 Feb; 21(2):161-9. PubMed ID: 22011208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro release profiles of clonidine transdermal therapeutic systems and scopolamine transdermal patches.
    Shah VP; Tymes NW; Skelly JP
    Pharm Res; 1989 Apr; 6(4):346-51. PubMed ID: 2748524
    [No Abstract]   [Full Text] [Related]  

  • 40. Transdermal Drug Delivery Systems (TDDS): Recent Advances and Failure Modes.
    Ghaferi M; Alavi SE; Phan K; Maibach H; Mohammed Y
    Mol Pharm; 2024 Nov; 21(11):5373-5391. PubMed ID: 39365887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.